Taken together, DEGs and immune related signatures identified in MSI-H altered CRC patients suggested that the upregulation of multiple pro-inflammatory signals accompanied by the expression of PD-1 and PD-L1 contribute to an immune “active” tumor microenvironment that can be successfully modulated by the ICIs therapy. This evidence concerns the gene PDCD1 and neoplasm.